Global Circulating Tumour DNA (ctDNA) Testing Market Growth (Status and Outlook) 2026-2032
The global Circulating Tumour DNA (ctDNA) Testing market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Circulating tumor DNA (ctDNA) is found in the bloodstream and refers to DNA that comes from cancerous cells and tumors. Most DNA is inside a cell?s nucleus. As a tumor grows, cells die and are replaced by new ones. The dead cells get broken down and their contents, including DNA, are released into the bloodstream. ctDNA are small pieces of DNA, usually comprising fewer than 200 building blocks (nucleotides) in length.The quantity of ctDNA varies among individuals and depends on the type of tumor, its location, and for cancerous tumors, the cancer stage.Circulating-tumor DNA (ctDNA) refers to fragments of DNA derived from tumor cells and circulating in the blood together with cell-free DNA from other sources. Circulating tumor DNA (ctDNA) analyses are minimally invasive and accessible for risk stratification or treatment response monitoring of cancer patients. Compared to tumor biopsy analysis, they are not only less invasive, but also provide a more representative picture, allowing capturing both tumor heterogeneity and multiple tumor sites.
United States market for Circulating Tumour DNA (ctDNA) Testing is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Circulating Tumour DNA (ctDNA) Testing is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Circulating Tumour DNA (ctDNA) Testing is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Circulating Tumour DNA (ctDNA) Testing players cover Nexomics, Roche, ORIOMICS, Signatera, Illumina, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the ?Circulating Tumour DNA (ctDNA) Testing Industry Forecast? looks at past sales and reviews total world Circulating Tumour DNA (ctDNA) Testing sales in 2025, providing a comprehensive analysis by region and market sector of projected Circulating Tumour DNA (ctDNA) Testing sales for 2026 through 2032. With Circulating Tumour DNA (ctDNA) Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Circulating Tumour DNA (ctDNA) Testing industry.
This Insight Report provides a comprehensive analysis of the global Circulating Tumour DNA (ctDNA) Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Circulating Tumour DNA (ctDNA) Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Circulating Tumour DNA (ctDNA) Testing market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Circulating Tumour DNA (ctDNA) Testing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Circulating Tumour DNA (ctDNA) Testing.
This report presents a comprehensive overview, market shares, and growth opportunities of Circulating Tumour DNA (ctDNA) Testing market by product type, application, key players and key regions and countries.
Segmentation by Type:
Circulating tumor DNA (ctDNA) is found in the bloodstream and refers to DNA that comes from cancerous cells and tumors. Most DNA is inside a cell?s nucleus. As a tumor grows, cells die and are replaced by new ones. The dead cells get broken down and their contents, including DNA, are released into the bloodstream. ctDNA are small pieces of DNA, usually comprising fewer than 200 building blocks (nucleotides) in length.The quantity of ctDNA varies among individuals and depends on the type of tumor, its location, and for cancerous tumors, the cancer stage.Circulating-tumor DNA (ctDNA) refers to fragments of DNA derived from tumor cells and circulating in the blood together with cell-free DNA from other sources. Circulating tumor DNA (ctDNA) analyses are minimally invasive and accessible for risk stratification or treatment response monitoring of cancer patients. Compared to tumor biopsy analysis, they are not only less invasive, but also provide a more representative picture, allowing capturing both tumor heterogeneity and multiple tumor sites.
United States market for Circulating Tumour DNA (ctDNA) Testing is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Circulating Tumour DNA (ctDNA) Testing is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Circulating Tumour DNA (ctDNA) Testing is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Circulating Tumour DNA (ctDNA) Testing players cover Nexomics, Roche, ORIOMICS, Signatera, Illumina, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the ?Circulating Tumour DNA (ctDNA) Testing Industry Forecast? looks at past sales and reviews total world Circulating Tumour DNA (ctDNA) Testing sales in 2025, providing a comprehensive analysis by region and market sector of projected Circulating Tumour DNA (ctDNA) Testing sales for 2026 through 2032. With Circulating Tumour DNA (ctDNA) Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Circulating Tumour DNA (ctDNA) Testing industry.
This Insight Report provides a comprehensive analysis of the global Circulating Tumour DNA (ctDNA) Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Circulating Tumour DNA (ctDNA) Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Circulating Tumour DNA (ctDNA) Testing market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Circulating Tumour DNA (ctDNA) Testing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Circulating Tumour DNA (ctDNA) Testing.
This report presents a comprehensive overview, market shares, and growth opportunities of Circulating Tumour DNA (ctDNA) Testing market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Gastric Cancer Methylation Screening
- Esophageal Cancer Methylation Screening
- Colorectal Cancer Methylation Screening
- Lung Cancer Methylation Screening
- Liver Cancer Methylation Screening
- Other Cancer Screening
- Hospital
- Medical Center
- Laboratory
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Nexomics
- Roche
- ORIOMICS
- Signatera
- Illumina
- Sysmex Corporation
- Bio-Rad
- Biocartis
- QIAGEN
- GuardantHealth
- GSK plc
- AstraZeneca
- NeoGenomics Laboratories
- AmoyDx
- Annoroad
- Burning Rock Biotech
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Circulating Tumour DNA (ctDNA) Testing Market Size (2021-2032)
2.1.2 Circulating Tumour DNA (ctDNA) Testing Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Circulating Tumour DNA (ctDNA) Testing by Country/Region (2021, 2025 & 2032)
2.2 Circulating Tumour DNA (ctDNA) Testing Segment by Type
2.2.1 Gastric Cancer Methylation Screening
2.2.2 Esophageal Cancer Methylation Screening
2.2.3 Colorectal Cancer Methylation Screening
2.2.4 Lung Cancer Methylation Screening
2.2.5 Liver Cancer Methylation Screening
2.2.6 Other Cancer Screening
2.2.7 Circulating Tumour DNA (ctDNA) Testing Market Size by Type
2.2.7.1 Circulating Tumour DNA (ctDNA) Testing Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.7.2 Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Type (2021-2026)
2.3 Circulating Tumour DNA (ctDNA) Testing Segment by Application
2.3.1 Hospital
2.3.2 Medical Center
2.3.3 Laboratory
2.3.4 Circulating Tumour DNA (ctDNA) Testing Market Size by Application
2.3.4.1 Circulating Tumour DNA (ctDNA) Testing Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Application (2021-2026)
3 CIRCULATING TUMOUR DNA (CTDNA) TESTING MARKET SIZE BY PLAYER
3.1 Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Player
3.1.1 Global Circulating Tumour DNA (ctDNA) Testing Revenue by Player (2021-2026)
3.1.2 Global Circulating Tumour DNA (ctDNA) Testing Revenue Market Share by Player (2021-2026)
3.2 Global Circulating Tumour DNA (ctDNA) Testing Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 CIRCULATING TUMOUR DNA (CTDNA) TESTING BY REGION
4.1 Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2021-2026)
4.2 Global Circulating Tumour DNA (ctDNA) Testing Annual Revenue by Country/Region (2021-2026)
4.3 Americas Circulating Tumour DNA (ctDNA) Testing Market Size Growth (2021-2026)
4.4 APAC Circulating Tumour DNA (ctDNA) Testing Market Size Growth (2021-2026)
4.5 Europe Circulating Tumour DNA (ctDNA) Testing Market Size Growth (2021-2026)
4.6 Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2021-2026)
5.2 Americas Circulating Tumour DNA (ctDNA) Testing Market Size by Type (2021-2026)
5.3 Americas Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2021-2026)
6.2 APAC Circulating Tumour DNA (ctDNA) Testing Market Size by Type (2021-2026)
6.3 APAC Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2021-2026)
7.2 Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Type (2021-2026)
7.3 Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Circulating Tumour DNA (ctDNA) Testing by Region (2021-2026)
8.2 Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size by Type (2021-2026)
8.3 Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL CIRCULATING TUMOUR DNA (CTDNA) TESTING MARKET FORECAST
10.1 Global Circulating Tumour DNA (ctDNA) Testing Forecast by Region (2027-2032)
10.1.1 Global Circulating Tumour DNA (ctDNA) Testing Forecast by Region (2027-2032)
10.1.2 Americas Circulating Tumour DNA (ctDNA) Testing Forecast
10.1.3 APAC Circulating Tumour DNA (ctDNA) Testing Forecast
10.1.4 Europe Circulating Tumour DNA (ctDNA) Testing Forecast
10.1.5 Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Forecast
10.2 Americas Circulating Tumour DNA (ctDNA) Testing Forecast by Country (2027-2032)
10.2.1 United States Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.2.2 Canada Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.2.3 Mexico Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.2.4 Brazil Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.3 APAC Circulating Tumour DNA (ctDNA) Testing Forecast by Region (2027-2032)
10.3.1 China Circulating Tumour DNA (ctDNA) Testing Market Forecast
10.3.2 Japan Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.3.3 Korea Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.3.4 Southeast Asia Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.3.5 India Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.3.6 Australia Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.4 Europe Circulating Tumour DNA (ctDNA) Testing Forecast by Country (2027-2032)
10.4.1 Germany Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.4.2 France Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.4.3 UK Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.4.4 Italy Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.4.5 Russia Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.5 Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Forecast by Region (2027-2032)
10.5.1 Egypt Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.5.2 South Africa Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.5.3 Israel Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.5.4 Turkey Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.6 Global Circulating Tumour DNA (ctDNA) Testing Forecast by Type (2027-2032)
10.7 Global Circulating Tumour DNA (ctDNA) Testing Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Circulating Tumour DNA (ctDNA) Testing Forecast
11 KEY PLAYERS ANALYSIS
11.1 Nexomics
11.1.1 Nexomics Company Information
11.1.2 Nexomics Circulating Tumour DNA (ctDNA) Testing Product Offered
11.1.3 Nexomics Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Nexomics Main Business Overview
11.1.5 Nexomics Latest Developments
11.2 Roche
11.2.1 Roche Company Information
11.2.2 Roche Circulating Tumour DNA (ctDNA) Testing Product Offered
11.2.3 Roche Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Roche Main Business Overview
11.2.5 Roche Latest Developments
11.3 ORIOMICS
11.3.1 ORIOMICS Company Information
11.3.2 ORIOMICS Circulating Tumour DNA (ctDNA) Testing Product Offered
11.3.3 ORIOMICS Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 ORIOMICS Main Business Overview
11.3.5 ORIOMICS Latest Developments
11.4 Signatera
11.4.1 Signatera Company Information
11.4.2 Signatera Circulating Tumour DNA (ctDNA) Testing Product Offered
11.4.3 Signatera Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Signatera Main Business Overview
11.4.5 Signatera Latest Developments
11.5 Illumina
11.5.1 Illumina Company Information
11.5.2 Illumina Circulating Tumour DNA (ctDNA) Testing Product Offered
11.5.3 Illumina Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Illumina Main Business Overview
11.5.5 Illumina Latest Developments
11.6 Sysmex Corporation
11.6.1 Sysmex Corporation Company Information
11.6.2 Sysmex Corporation Circulating Tumour DNA (ctDNA) Testing Product Offered
11.6.3 Sysmex Corporation Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Sysmex Corporation Main Business Overview
11.6.5 Sysmex Corporation Latest Developments
11.7 Bio-Rad
11.7.1 Bio-Rad Company Information
11.7.2 Bio-Rad Circulating Tumour DNA (ctDNA) Testing Product Offered
11.7.3 Bio-Rad Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Bio-Rad Main Business Overview
11.7.5 Bio-Rad Latest Developments
11.8 Biocartis
11.8.1 Biocartis Company Information
11.8.2 Biocartis Circulating Tumour DNA (ctDNA) Testing Product Offered
11.8.3 Biocartis Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Biocartis Main Business Overview
11.8.5 Biocartis Latest Developments
11.9 QIAGEN
11.9.1 QIAGEN Company Information
11.9.2 QIAGEN Circulating Tumour DNA (ctDNA) Testing Product Offered
11.9.3 QIAGEN Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 QIAGEN Main Business Overview
11.9.5 QIAGEN Latest Developments
11.10 GuardantHealth
11.10.1 GuardantHealth Company Information
11.10.2 GuardantHealth Circulating Tumour DNA (ctDNA) Testing Product Offered
11.10.3 GuardantHealth Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 GuardantHealth Main Business Overview
11.10.5 GuardantHealth Latest Developments
11.11 GSK plc
11.11.1 GSK plc Company Information
11.11.2 GSK plc Circulating Tumour DNA (ctDNA) Testing Product Offered
11.11.3 GSK plc Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 GSK plc Main Business Overview
11.11.5 GSK plc Latest Developments
11.12 AstraZeneca
11.12.1 AstraZeneca Company Information
11.12.2 AstraZeneca Circulating Tumour DNA (ctDNA) Testing Product Offered
11.12.3 AstraZeneca Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 AstraZeneca Main Business Overview
11.12.5 AstraZeneca Latest Developments
11.13 NeoGenomics Laboratories
11.13.1 NeoGenomics Laboratories Company Information
11.13.2 NeoGenomics Laboratories Circulating Tumour DNA (ctDNA) Testing Product Offered
11.13.3 NeoGenomics Laboratories Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 NeoGenomics Laboratories Main Business Overview
11.13.5 NeoGenomics Laboratories Latest Developments
11.14 AmoyDx
11.14.1 AmoyDx Company Information
11.14.2 AmoyDx Circulating Tumour DNA (ctDNA) Testing Product Offered
11.14.3 AmoyDx Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 AmoyDx Main Business Overview
11.14.5 AmoyDx Latest Developments
11.15 Annoroad
11.15.1 Annoroad Company Information
11.15.2 Annoroad Circulating Tumour DNA (ctDNA) Testing Product Offered
11.15.3 Annoroad Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Annoroad Main Business Overview
11.15.5 Annoroad Latest Developments
11.16 Burning Rock Biotech
11.16.1 Burning Rock Biotech Company Information
11.16.2 Burning Rock Biotech Circulating Tumour DNA (ctDNA) Testing Product Offered
11.16.3 Burning Rock Biotech Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Burning Rock Biotech Main Business Overview
11.16.5 Burning Rock Biotech Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Circulating Tumour DNA (ctDNA) Testing Market Size (2021-2032)
2.1.2 Circulating Tumour DNA (ctDNA) Testing Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Circulating Tumour DNA (ctDNA) Testing by Country/Region (2021, 2025 & 2032)
2.2 Circulating Tumour DNA (ctDNA) Testing Segment by Type
2.2.1 Gastric Cancer Methylation Screening
2.2.2 Esophageal Cancer Methylation Screening
2.2.3 Colorectal Cancer Methylation Screening
2.2.4 Lung Cancer Methylation Screening
2.2.5 Liver Cancer Methylation Screening
2.2.6 Other Cancer Screening
2.2.7 Circulating Tumour DNA (ctDNA) Testing Market Size by Type
2.2.7.1 Circulating Tumour DNA (ctDNA) Testing Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.7.2 Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Type (2021-2026)
2.3 Circulating Tumour DNA (ctDNA) Testing Segment by Application
2.3.1 Hospital
2.3.2 Medical Center
2.3.3 Laboratory
2.3.4 Circulating Tumour DNA (ctDNA) Testing Market Size by Application
2.3.4.1 Circulating Tumour DNA (ctDNA) Testing Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Application (2021-2026)
3 CIRCULATING TUMOUR DNA (CTDNA) TESTING MARKET SIZE BY PLAYER
3.1 Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Player
3.1.1 Global Circulating Tumour DNA (ctDNA) Testing Revenue by Player (2021-2026)
3.1.2 Global Circulating Tumour DNA (ctDNA) Testing Revenue Market Share by Player (2021-2026)
3.2 Global Circulating Tumour DNA (ctDNA) Testing Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 CIRCULATING TUMOUR DNA (CTDNA) TESTING BY REGION
4.1 Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2021-2026)
4.2 Global Circulating Tumour DNA (ctDNA) Testing Annual Revenue by Country/Region (2021-2026)
4.3 Americas Circulating Tumour DNA (ctDNA) Testing Market Size Growth (2021-2026)
4.4 APAC Circulating Tumour DNA (ctDNA) Testing Market Size Growth (2021-2026)
4.5 Europe Circulating Tumour DNA (ctDNA) Testing Market Size Growth (2021-2026)
4.6 Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2021-2026)
5.2 Americas Circulating Tumour DNA (ctDNA) Testing Market Size by Type (2021-2026)
5.3 Americas Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2021-2026)
6.2 APAC Circulating Tumour DNA (ctDNA) Testing Market Size by Type (2021-2026)
6.3 APAC Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2021-2026)
7.2 Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Type (2021-2026)
7.3 Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Circulating Tumour DNA (ctDNA) Testing by Region (2021-2026)
8.2 Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size by Type (2021-2026)
8.3 Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL CIRCULATING TUMOUR DNA (CTDNA) TESTING MARKET FORECAST
10.1 Global Circulating Tumour DNA (ctDNA) Testing Forecast by Region (2027-2032)
10.1.1 Global Circulating Tumour DNA (ctDNA) Testing Forecast by Region (2027-2032)
10.1.2 Americas Circulating Tumour DNA (ctDNA) Testing Forecast
10.1.3 APAC Circulating Tumour DNA (ctDNA) Testing Forecast
10.1.4 Europe Circulating Tumour DNA (ctDNA) Testing Forecast
10.1.5 Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Forecast
10.2 Americas Circulating Tumour DNA (ctDNA) Testing Forecast by Country (2027-2032)
10.2.1 United States Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.2.2 Canada Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.2.3 Mexico Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.2.4 Brazil Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.3 APAC Circulating Tumour DNA (ctDNA) Testing Forecast by Region (2027-2032)
10.3.1 China Circulating Tumour DNA (ctDNA) Testing Market Forecast
10.3.2 Japan Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.3.3 Korea Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.3.4 Southeast Asia Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.3.5 India Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.3.6 Australia Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.4 Europe Circulating Tumour DNA (ctDNA) Testing Forecast by Country (2027-2032)
10.4.1 Germany Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.4.2 France Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.4.3 UK Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.4.4 Italy Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.4.5 Russia Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.5 Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Forecast by Region (2027-2032)
10.5.1 Egypt Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.5.2 South Africa Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.5.3 Israel Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.5.4 Turkey Market Circulating Tumour DNA (ctDNA) Testing Forecast
10.6 Global Circulating Tumour DNA (ctDNA) Testing Forecast by Type (2027-2032)
10.7 Global Circulating Tumour DNA (ctDNA) Testing Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Circulating Tumour DNA (ctDNA) Testing Forecast
11 KEY PLAYERS ANALYSIS
11.1 Nexomics
11.1.1 Nexomics Company Information
11.1.2 Nexomics Circulating Tumour DNA (ctDNA) Testing Product Offered
11.1.3 Nexomics Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Nexomics Main Business Overview
11.1.5 Nexomics Latest Developments
11.2 Roche
11.2.1 Roche Company Information
11.2.2 Roche Circulating Tumour DNA (ctDNA) Testing Product Offered
11.2.3 Roche Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Roche Main Business Overview
11.2.5 Roche Latest Developments
11.3 ORIOMICS
11.3.1 ORIOMICS Company Information
11.3.2 ORIOMICS Circulating Tumour DNA (ctDNA) Testing Product Offered
11.3.3 ORIOMICS Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 ORIOMICS Main Business Overview
11.3.5 ORIOMICS Latest Developments
11.4 Signatera
11.4.1 Signatera Company Information
11.4.2 Signatera Circulating Tumour DNA (ctDNA) Testing Product Offered
11.4.3 Signatera Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Signatera Main Business Overview
11.4.5 Signatera Latest Developments
11.5 Illumina
11.5.1 Illumina Company Information
11.5.2 Illumina Circulating Tumour DNA (ctDNA) Testing Product Offered
11.5.3 Illumina Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Illumina Main Business Overview
11.5.5 Illumina Latest Developments
11.6 Sysmex Corporation
11.6.1 Sysmex Corporation Company Information
11.6.2 Sysmex Corporation Circulating Tumour DNA (ctDNA) Testing Product Offered
11.6.3 Sysmex Corporation Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Sysmex Corporation Main Business Overview
11.6.5 Sysmex Corporation Latest Developments
11.7 Bio-Rad
11.7.1 Bio-Rad Company Information
11.7.2 Bio-Rad Circulating Tumour DNA (ctDNA) Testing Product Offered
11.7.3 Bio-Rad Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Bio-Rad Main Business Overview
11.7.5 Bio-Rad Latest Developments
11.8 Biocartis
11.8.1 Biocartis Company Information
11.8.2 Biocartis Circulating Tumour DNA (ctDNA) Testing Product Offered
11.8.3 Biocartis Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Biocartis Main Business Overview
11.8.5 Biocartis Latest Developments
11.9 QIAGEN
11.9.1 QIAGEN Company Information
11.9.2 QIAGEN Circulating Tumour DNA (ctDNA) Testing Product Offered
11.9.3 QIAGEN Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 QIAGEN Main Business Overview
11.9.5 QIAGEN Latest Developments
11.10 GuardantHealth
11.10.1 GuardantHealth Company Information
11.10.2 GuardantHealth Circulating Tumour DNA (ctDNA) Testing Product Offered
11.10.3 GuardantHealth Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 GuardantHealth Main Business Overview
11.10.5 GuardantHealth Latest Developments
11.11 GSK plc
11.11.1 GSK plc Company Information
11.11.2 GSK plc Circulating Tumour DNA (ctDNA) Testing Product Offered
11.11.3 GSK plc Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 GSK plc Main Business Overview
11.11.5 GSK plc Latest Developments
11.12 AstraZeneca
11.12.1 AstraZeneca Company Information
11.12.2 AstraZeneca Circulating Tumour DNA (ctDNA) Testing Product Offered
11.12.3 AstraZeneca Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 AstraZeneca Main Business Overview
11.12.5 AstraZeneca Latest Developments
11.13 NeoGenomics Laboratories
11.13.1 NeoGenomics Laboratories Company Information
11.13.2 NeoGenomics Laboratories Circulating Tumour DNA (ctDNA) Testing Product Offered
11.13.3 NeoGenomics Laboratories Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 NeoGenomics Laboratories Main Business Overview
11.13.5 NeoGenomics Laboratories Latest Developments
11.14 AmoyDx
11.14.1 AmoyDx Company Information
11.14.2 AmoyDx Circulating Tumour DNA (ctDNA) Testing Product Offered
11.14.3 AmoyDx Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 AmoyDx Main Business Overview
11.14.5 AmoyDx Latest Developments
11.15 Annoroad
11.15.1 Annoroad Company Information
11.15.2 Annoroad Circulating Tumour DNA (ctDNA) Testing Product Offered
11.15.3 Annoroad Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Annoroad Main Business Overview
11.15.5 Annoroad Latest Developments
11.16 Burning Rock Biotech
11.16.1 Burning Rock Biotech Company Information
11.16.2 Burning Rock Biotech Circulating Tumour DNA (ctDNA) Testing Product Offered
11.16.3 Burning Rock Biotech Circulating Tumour DNA (ctDNA) Testing Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Burning Rock Biotech Main Business Overview
11.16.5 Burning Rock Biotech Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Circulating Tumour DNA (ctDNA) Testing Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Circulating Tumour DNA (ctDNA) Testing Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Gastric Cancer Methylation Screening
Table 4. Major Players of Esophageal Cancer Methylation Screening
Table 5. Major Players of Colorectal Cancer Methylation Screening
Table 6. Major Players of Lung Cancer Methylation Screening
Table 7. Major Players of Liver Cancer Methylation Screening
Table 8. Major Players of Other Cancer Screening
Table 9. Circulating Tumour DNA (ctDNA) Testing Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global Circulating Tumour DNA (ctDNA) Testing Market Size by Type (2021-2026) & ($ millions)
Table 11. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Type (2021-2026)
Table 12. Circulating Tumour DNA (ctDNA) Testing Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 13. Global Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2021-2026) & ($ millions)
Table 14. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Application (2021-2026)
Table 15. Global Circulating Tumour DNA (ctDNA) Testing Revenue by Player (2021-2026) & ($ millions)
Table 16. Global Circulating Tumour DNA (ctDNA) Testing Revenue Market Share by Player (2021-2026)
Table 17. Circulating Tumour DNA (ctDNA) Testing Key Players Head office and Products Offered
Table 18. Circulating Tumour DNA (ctDNA) Testing Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 19. New Products and Potential Entrants
Table 20. Mergers & Acquisitions, Expansion
Table 21. Global Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2021-2026) & ($ millions)
Table 22. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Region (2021-2026)
Table 23. Global Circulating Tumour DNA (ctDNA) Testing Revenue by Country/Region (2021-2026) & ($ millions)
Table 24. Global Circulating Tumour DNA (ctDNA) Testing Revenue Market Share by Country/Region (2021-2026)
Table 25. Americas Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2021-2026) & ($ millions)
Table 26. Americas Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Country (2021-2026)
Table 27. Americas Circulating Tumour DNA (ctDNA) Testing Market Size by Type (2021-2026) & ($ millions)
Table 28. Americas Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Type (2021-2026)
Table 29. Americas Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2021-2026) & ($ millions)
Table 30. Americas Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Application (2021-2026)
Table 31. APAC Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2021-2026) & ($ millions)
Table 32. APAC Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Region (2021-2026)
Table 33. APAC Circulating Tumour DNA (ctDNA) Testing Market Size by Type (2021-2026) & ($ millions)
Table 34. APAC Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2021-2026) & ($ millions)
Table 35. Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2021-2026) & ($ millions)
Table 36. Europe Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Country (2021-2026)
Table 37. Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Type (2021-2026) & ($ millions)
Table 38. Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2021-2026) & ($ millions)
Table 39. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2021-2026) & ($ millions)
Table 40. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size by Type (2021-2026) & ($ millions)
Table 41. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2021-2026) & ($ millions)
Table 42. Key Market Drivers & Growth Opportunities of Circulating Tumour DNA (ctDNA) Testing
Table 43. Key Market Challenges & Risks of Circulating Tumour DNA (ctDNA) Testing
Table 44. Key Industry Trends of Circulating Tumour DNA (ctDNA) Testing
Table 45. Global Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Region (2027-2032) & ($ millions)
Table 46. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share Forecast by Region (2027-2032)
Table 47. Global Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Type (2027-2032) & ($ millions)
Table 48. Global Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Application (2027-2032) & ($ millions)
Table 49. Nexomics Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 50. Nexomics Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 51. Nexomics Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 52. Nexomics Main Business
Table 53. Nexomics Latest Developments
Table 54. Roche Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 55. Roche Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 56. Roche Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 57. Roche Main Business
Table 58. Roche Latest Developments
Table 59. ORIOMICS Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 60. ORIOMICS Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 61. ORIOMICS Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 62. ORIOMICS Main Business
Table 63. ORIOMICS Latest Developments
Table 64. Signatera Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 65. Signatera Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 66. Signatera Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 67. Signatera Main Business
Table 68. Signatera Latest Developments
Table 69. Illumina Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 70. Illumina Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 71. Illumina Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 72. Illumina Main Business
Table 73. Illumina Latest Developments
Table 74. Sysmex Corporation Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 75. Sysmex Corporation Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 76. Sysmex Corporation Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 77. Sysmex Corporation Main Business
Table 78. Sysmex Corporation Latest Developments
Table 79. Bio-Rad Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 80. Bio-Rad Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 81. Bio-Rad Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 82. Bio-Rad Main Business
Table 83. Bio-Rad Latest Developments
Table 84. Biocartis Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 85. Biocartis Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 86. Biocartis Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 87. Biocartis Main Business
Table 88. Biocartis Latest Developments
Table 89. QIAGEN Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 90. QIAGEN Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 91. QIAGEN Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 92. QIAGEN Main Business
Table 93. QIAGEN Latest Developments
Table 94. GuardantHealth Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 95. GuardantHealth Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 96. GuardantHealth Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 97. GuardantHealth Main Business
Table 98. GuardantHealth Latest Developments
Table 99. GSK plc Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 100. GSK plc Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 101. GSK plc Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 102. GSK plc Main Business
Table 103. GSK plc Latest Developments
Table 104. AstraZeneca Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 105. AstraZeneca Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 106. AstraZeneca Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 107. AstraZeneca Main Business
Table 108. AstraZeneca Latest Developments
Table 109. NeoGenomics Laboratories Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 110. NeoGenomics Laboratories Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 111. NeoGenomics Laboratories Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 112. NeoGenomics Laboratories Main Business
Table 113. NeoGenomics Laboratories Latest Developments
Table 114. AmoyDx Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 115. AmoyDx Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 116. AmoyDx Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 117. AmoyDx Main Business
Table 118. AmoyDx Latest Developments
Table 119. Annoroad Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 120. Annoroad Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 121. Annoroad Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 122. Annoroad Main Business
Table 123. Annoroad Latest Developments
Table 124. Burning Rock Biotech Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 125. Burning Rock Biotech Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 126. Burning Rock Biotech Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 127. Burning Rock Biotech Main Business
Table 128. Burning Rock Biotech Latest Developments
Table 1. Circulating Tumour DNA (ctDNA) Testing Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Circulating Tumour DNA (ctDNA) Testing Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Gastric Cancer Methylation Screening
Table 4. Major Players of Esophageal Cancer Methylation Screening
Table 5. Major Players of Colorectal Cancer Methylation Screening
Table 6. Major Players of Lung Cancer Methylation Screening
Table 7. Major Players of Liver Cancer Methylation Screening
Table 8. Major Players of Other Cancer Screening
Table 9. Circulating Tumour DNA (ctDNA) Testing Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global Circulating Tumour DNA (ctDNA) Testing Market Size by Type (2021-2026) & ($ millions)
Table 11. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Type (2021-2026)
Table 12. Circulating Tumour DNA (ctDNA) Testing Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 13. Global Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2021-2026) & ($ millions)
Table 14. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Application (2021-2026)
Table 15. Global Circulating Tumour DNA (ctDNA) Testing Revenue by Player (2021-2026) & ($ millions)
Table 16. Global Circulating Tumour DNA (ctDNA) Testing Revenue Market Share by Player (2021-2026)
Table 17. Circulating Tumour DNA (ctDNA) Testing Key Players Head office and Products Offered
Table 18. Circulating Tumour DNA (ctDNA) Testing Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 19. New Products and Potential Entrants
Table 20. Mergers & Acquisitions, Expansion
Table 21. Global Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2021-2026) & ($ millions)
Table 22. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Region (2021-2026)
Table 23. Global Circulating Tumour DNA (ctDNA) Testing Revenue by Country/Region (2021-2026) & ($ millions)
Table 24. Global Circulating Tumour DNA (ctDNA) Testing Revenue Market Share by Country/Region (2021-2026)
Table 25. Americas Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2021-2026) & ($ millions)
Table 26. Americas Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Country (2021-2026)
Table 27. Americas Circulating Tumour DNA (ctDNA) Testing Market Size by Type (2021-2026) & ($ millions)
Table 28. Americas Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Type (2021-2026)
Table 29. Americas Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2021-2026) & ($ millions)
Table 30. Americas Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Application (2021-2026)
Table 31. APAC Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2021-2026) & ($ millions)
Table 32. APAC Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Region (2021-2026)
Table 33. APAC Circulating Tumour DNA (ctDNA) Testing Market Size by Type (2021-2026) & ($ millions)
Table 34. APAC Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2021-2026) & ($ millions)
Table 35. Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2021-2026) & ($ millions)
Table 36. Europe Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Country (2021-2026)
Table 37. Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Type (2021-2026) & ($ millions)
Table 38. Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2021-2026) & ($ millions)
Table 39. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2021-2026) & ($ millions)
Table 40. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size by Type (2021-2026) & ($ millions)
Table 41. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2021-2026) & ($ millions)
Table 42. Key Market Drivers & Growth Opportunities of Circulating Tumour DNA (ctDNA) Testing
Table 43. Key Market Challenges & Risks of Circulating Tumour DNA (ctDNA) Testing
Table 44. Key Industry Trends of Circulating Tumour DNA (ctDNA) Testing
Table 45. Global Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Region (2027-2032) & ($ millions)
Table 46. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share Forecast by Region (2027-2032)
Table 47. Global Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Type (2027-2032) & ($ millions)
Table 48. Global Circulating Tumour DNA (ctDNA) Testing Market Size Forecast by Application (2027-2032) & ($ millions)
Table 49. Nexomics Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 50. Nexomics Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 51. Nexomics Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 52. Nexomics Main Business
Table 53. Nexomics Latest Developments
Table 54. Roche Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 55. Roche Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 56. Roche Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 57. Roche Main Business
Table 58. Roche Latest Developments
Table 59. ORIOMICS Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 60. ORIOMICS Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 61. ORIOMICS Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 62. ORIOMICS Main Business
Table 63. ORIOMICS Latest Developments
Table 64. Signatera Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 65. Signatera Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 66. Signatera Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 67. Signatera Main Business
Table 68. Signatera Latest Developments
Table 69. Illumina Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 70. Illumina Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 71. Illumina Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 72. Illumina Main Business
Table 73. Illumina Latest Developments
Table 74. Sysmex Corporation Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 75. Sysmex Corporation Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 76. Sysmex Corporation Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 77. Sysmex Corporation Main Business
Table 78. Sysmex Corporation Latest Developments
Table 79. Bio-Rad Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 80. Bio-Rad Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 81. Bio-Rad Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 82. Bio-Rad Main Business
Table 83. Bio-Rad Latest Developments
Table 84. Biocartis Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 85. Biocartis Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 86. Biocartis Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 87. Biocartis Main Business
Table 88. Biocartis Latest Developments
Table 89. QIAGEN Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 90. QIAGEN Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 91. QIAGEN Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 92. QIAGEN Main Business
Table 93. QIAGEN Latest Developments
Table 94. GuardantHealth Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 95. GuardantHealth Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 96. GuardantHealth Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 97. GuardantHealth Main Business
Table 98. GuardantHealth Latest Developments
Table 99. GSK plc Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 100. GSK plc Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 101. GSK plc Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 102. GSK plc Main Business
Table 103. GSK plc Latest Developments
Table 104. AstraZeneca Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 105. AstraZeneca Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 106. AstraZeneca Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 107. AstraZeneca Main Business
Table 108. AstraZeneca Latest Developments
Table 109. NeoGenomics Laboratories Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 110. NeoGenomics Laboratories Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 111. NeoGenomics Laboratories Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 112. NeoGenomics Laboratories Main Business
Table 113. NeoGenomics Laboratories Latest Developments
Table 114. AmoyDx Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 115. AmoyDx Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 116. AmoyDx Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 117. AmoyDx Main Business
Table 118. AmoyDx Latest Developments
Table 119. Annoroad Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 120. Annoroad Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 121. Annoroad Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 122. Annoroad Main Business
Table 123. Annoroad Latest Developments
Table 124. Burning Rock Biotech Details, Company Type, Circulating Tumour DNA (ctDNA) Testing Area Served and Its Competitors
Table 125. Burning Rock Biotech Circulating Tumour DNA (ctDNA) Testing Product Offered
Table 126. Burning Rock Biotech Circulating Tumour DNA (ctDNA) Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 127. Burning Rock Biotech Main Business
Table 128. Burning Rock Biotech Latest Developments
LIST OF FIGURES
Figure 1. Circulating Tumour DNA (ctDNA) Testing Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Circulating Tumour DNA (ctDNA) Testing Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Circulating Tumour DNA (ctDNA) Testing Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Country/Region (2025)
Figure 8. Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Type in 2025
Figure 10. Circulating Tumour DNA (ctDNA) Testing in Hospital
Figure 11. Global Circulating Tumour DNA (ctDNA) Testing Market: Hospital (2021-2026) & ($ millions)
Figure 12. Circulating Tumour DNA (ctDNA) Testing in Medical Center
Figure 13. Global Circulating Tumour DNA (ctDNA) Testing Market: Medical Center (2021-2026) & ($ millions)
Figure 14. Circulating Tumour DNA (ctDNA) Testing in Laboratory
Figure 15. Global Circulating Tumour DNA (ctDNA) Testing Market: Laboratory (2021-2026) & ($ millions)
Figure 16. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Application in 2025
Figure 17. Global Circulating Tumour DNA (ctDNA) Testing Revenue Market Share by Player in 2025
Figure 18. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Region (2021-2026)
Figure 19. Americas Circulating Tumour DNA (ctDNA) Testing Market Size 2021-2026 ($ millions)
Figure 20. APAC Circulating Tumour DNA (ctDNA) Testing Market Size 2021-2026 ($ millions)
Figure 21. Europe Circulating Tumour DNA (ctDNA) Testing Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size 2021-2026 ($ millions)
Figure 23. Americas Circulating Tumour DNA (ctDNA) Testing Value Market Share by Country in 2025
Figure 24. United States Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Region in 2025
Figure 29. APAC Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Type (2021-2026)
Figure 30. APAC Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Application (2021-2026)
Figure 31. China Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 35. India Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Country in 2025
Figure 38. Europe Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Type (2021-2026)
Figure 39. Europe Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Application (2021-2026)
Figure 40. Germany Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 41. France Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 42. UK Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Application (2021-2026)
Figure 48. Egypt Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 54. APAC Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 55. Europe Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 57. United States Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 58. Canada Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 59. Mexico Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 60. Brazil Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 61. China Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 62. Japan Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 63. Korea Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 65. India Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 66. Australia Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 67. Germany Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 68. France Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 69. UK Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 70. Italy Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 71. Russia Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 72. Egypt Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 73. South Africa Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 74. Israel Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 75. Turkey Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 76. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 1. Circulating Tumour DNA (ctDNA) Testing Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Circulating Tumour DNA (ctDNA) Testing Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Circulating Tumour DNA (ctDNA) Testing Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Country/Region (2025)
Figure 8. Circulating Tumour DNA (ctDNA) Testing Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Type in 2025
Figure 10. Circulating Tumour DNA (ctDNA) Testing in Hospital
Figure 11. Global Circulating Tumour DNA (ctDNA) Testing Market: Hospital (2021-2026) & ($ millions)
Figure 12. Circulating Tumour DNA (ctDNA) Testing in Medical Center
Figure 13. Global Circulating Tumour DNA (ctDNA) Testing Market: Medical Center (2021-2026) & ($ millions)
Figure 14. Circulating Tumour DNA (ctDNA) Testing in Laboratory
Figure 15. Global Circulating Tumour DNA (ctDNA) Testing Market: Laboratory (2021-2026) & ($ millions)
Figure 16. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Application in 2025
Figure 17. Global Circulating Tumour DNA (ctDNA) Testing Revenue Market Share by Player in 2025
Figure 18. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Region (2021-2026)
Figure 19. Americas Circulating Tumour DNA (ctDNA) Testing Market Size 2021-2026 ($ millions)
Figure 20. APAC Circulating Tumour DNA (ctDNA) Testing Market Size 2021-2026 ($ millions)
Figure 21. Europe Circulating Tumour DNA (ctDNA) Testing Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size 2021-2026 ($ millions)
Figure 23. Americas Circulating Tumour DNA (ctDNA) Testing Value Market Share by Country in 2025
Figure 24. United States Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Region in 2025
Figure 29. APAC Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Type (2021-2026)
Figure 30. APAC Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Application (2021-2026)
Figure 31. China Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 35. India Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Country in 2025
Figure 38. Europe Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Type (2021-2026)
Figure 39. Europe Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Application (2021-2026)
Figure 40. Germany Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 41. France Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 42. UK Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size Market Share by Application (2021-2026)
Figure 48. Egypt Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries Circulating Tumour DNA (ctDNA) Testing Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 54. APAC Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 55. Europe Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 57. United States Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 58. Canada Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 59. Mexico Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 60. Brazil Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 61. China Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 62. Japan Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 63. Korea Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 65. India Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 66. Australia Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 67. Germany Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 68. France Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 69. UK Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 70. Italy Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 71. Russia Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 72. Egypt Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 73. South Africa Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 74. Israel Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 75. Turkey Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
Figure 76. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global Circulating Tumour DNA (ctDNA) Testing Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries Circulating Tumour DNA (ctDNA) Testing Market Size 2027-2032 ($ millions)
